Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Mesenchymal Stem Cells

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

British journal of haematology·2026

Same author

SOHO State of the Art Updates and Next Questions | Progress in Higher-Risk Myelodysplastic Syndromes.

Clinical lymphoma, myeloma & leukemia·2026

Same author

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Blood advances·2026

Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026

Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026

Same author

Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort Study.

JACC. Advances·2026

Search research articles

Related Experiment Video

Updated: Oct 4, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.

Peter L Greenberg¹, Richard M Stone², Aref Al-Kali³

¹1Stanford Cancer Institute.

Journal of the National Comprehensive Cancer Network : JNCCN

|February 7, 2022

Summary

The National Comprehensive Cancer Network (NCCN) updated its 2022 guidelines for Myelodysplastic Syndromes (MDS), offering new treatment strategies for both lower-risk and higher-risk patients. These updates also cover emerging therapies and genetic risk assessments for hereditary myeloid malignancies.

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

Related Experiment Videos

Last Updated: Oct 4, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

Area of Science:

Hematology
Oncology
Clinical Guidelines

Background:

Myelodysplastic Syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
Advances in understanding MDS biology and treatment necessitate regular guideline updates.

Purpose of the Study:

To summarize key updates in the 2022 NCCN Guidelines for Myelodysplastic Syndromes.
To highlight new recommendations for patient evaluation, diagnosis, and management.

Main Methods:

Annual review of clinical evidence by a multidisciplinary panel of MDS experts.
Inclusion of new biologic factors with prognostic significance.

Main Results:

Updated treatment recommendations for lower-risk and higher-risk MDS.
Inclusion of emerging therapies and supportive care strategies.
Enhanced genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.

Conclusions:

The 2022 NCCN Guidelines provide current, evidence-based recommendations for MDS management.
These updates reflect significant advances in MDS treatment and prognostic understanding.